{"nctId":"NCT00361569","briefTitle":"A Clinical Trial to Evaluate the Safety and Efficacy of DR-2041(Synthetic Conjugated Estrogens, A) for Treatment of Vulvovaginal Atrophy","startDateStruct":{"date":"2006-08"},"conditions":["Menopause"],"count":622,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: DR-2041a"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: DR-2041b"]},{"label":"3","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"name":"DR-2041a","otherNames":["Synthetic conjugated estrogens, A"]},{"name":"DR-2041b","otherNames":["Synthetic conjugated estrogens, A"]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Naturally or surgically menopausal\n* Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse)\n\nExclusion Criteria:\n\n* Known sensitivity or contraindication to estrogens or progestins\n* History or current diagnosis endometrial hyperplasia\n* Recent history of vaginal bleeding of unknown cause\n* Recent history or diagnosis of endometriosis\n* Any contraindication to estrogen therapy","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change in the Symptom Identified by the Patient to be Most Bothersome","description":"Change= Week 12 score - Baseline Score. The most bothersome symptom was derived from the subject self-assessment of vaginal atrophy, which consisted of 5 questions concerning severity of symptoms graded on a scale of 0-3(none, mild, moderate or severe) or 7 for not applicable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.71","spread":"0.0087"},{"groupId":"OG001","value":"-1.77","spread":"0.085"},{"groupId":"OG002","value":"-1.11","spread":"0.086"},{"groupId":"OG003","value":"-1.10","spread":"0.087"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Vaginal pH","description":"Change= Week 12 vaginal pH - Baseline vaginal pH","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"0.073"},{"groupId":"OG001","value":"-1.44","spread":"0.071"},{"groupId":"OG002","value":"-0.31","spread":"0.072"},{"groupId":"OG003","value":"-0.38","spread":"0.073"}]}]}]},{"type":"PRIMARY","title":"Mean Change in Maturation Index","description":"Change= Week 12 maturation index -baseline maturation index. Matuation index was calculated using the following equation: Maturation Index = (% Parabasal cells \\* 0) + (% Intermediate Cells \\* 0.5) + (% Superficial Cells \\* 1.0)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.46","spread":"1.221"},{"groupId":"OG001","value":"33.27","spread":"1.191"},{"groupId":"OG002","value":"5.16","spread":"1.205"},{"groupId":"OG003","value":"8.91","spread":"1.222"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability of DR-2041 (Synthetic Conjugated Estrogens, A)","description":"Any adverse event reported from the beginning of the 28-day screening through the subject's last report.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"87","spread":null},{"groupId":"OG002","value":"72","spread":null},{"groupId":"OG003","value":"77","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":150},"commonTop":["Upper Respiratory Tract Infection","Vulvovaginal Mycotic Infection","Urinary Tract Infection","Headache","Hot Flush"]}}}